Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab, Nivolumab, and Ipilimumab in Melanoma Brain Metastases
NCT06712927Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab, nivolumab and ipilimumab in melanoma (2 cohorts), sponsored by Stanford University. Primary endpoint: Intracranial clinical benefit rate at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06712927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712927.